Quick Answer
Cytek Biosciences, Inc. reported Gross Profit of $104.46 million for the year ending 2025.
- Cytek Biosciences, Inc. showed a decrease of -6.0% in Gross Profit from 2024 to 2025.
- This data is from Cytek Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $8.27 million | Q3 2020: $15.62 million | Q1 2021: $14.49 million | Q2 2021: $19.75 million | Q3 2021: $21.28 million | Q1 2022: $20.18 million | Q2 2022: $24.56 million | Q3 2022: $26.86 million | Q1 2023: $21.04 million | Q2 2023: $28.16 million | Q3 2023: $27.18 million | Q1 2024: $23.01 million | Q2 2024: $25.44 million | Q3 2024: $29.01 million | Q1 2025: $20.16 million | Q2 2025: $23.87 million | Q3 2025: $27.55 million.
- Over the full 6 years of available data (2020 to 2025), Cytek Biosciences, Inc.'s Gross Profit has grown by 102.0%.
- Historical annual values: Fiscal year 2025: $104.46 million | Fiscal year 2024: $111.11 million | Fiscal year 2023: $109.43 million | Fiscal year 2022: $100.97 million | Fiscal year 2021: $79.14 million | Fiscal year 2020: $51.71 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: